OncoSil Medical (ASX:OSL): Achieves record quarterly dose sales for its OncoSil device

Описание: OncoSil Medical (ASX:OSL) has reported strong progress in the clinical adoption for its OncoSil device used to treat pancreatic cancer after delivering a sharp increase in dose sales during the third quarter of the 2025 financial year (Q3 FY25). The company also notched up several other accomplishments in its efforts to bring the device to market in Europe and the UK.

🩺 Achieves quarterly record for OncoSil dose sales, up by 233% from the same time last year
⚕️Dose sales over the nine months to the end of Q3 FY25 up by 83% from the previous corresponding period
💉 Revenue for the first nine months of FY25 already exceeds total revenue for FY24, showcasing the sustained uplift in commercial sales
🩻 Defines commercialisation pathway for OncoSil device in Germany and the UK
🏥 Receives Medical Device Regulation (MDR) certification which is expected to help accelerate market penetration across the European Union and the UK

“We are thrilled by the strong uplift seen in OncoSil dose sales of the March 2025 quarter, which was a quarterly record. And the year-to-date growth in dose sales has been equally impressive, which has in turn flowed through to a much higher year-to-date revenue figure. These materially increased dose sales and revenue metrics reflect the increasing confidence in the OncoSil™ device among clinicians and the real-world impact it is having on patients’ lives." - Nigel Lange, OncoSil Medical Chief Executive Officer and Managing Director

ASX announcement ⚡ https://announcements.asx.com.au/asxp...